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Abstract
Background: The immune factors heat shock protein (HSP)/peptides (HSP/Ps) can induce both adaptive and
innate immune responses. Treatment with HSP/Ps in cancer cell-bearing mice and cancer patients revealed
antitumor immune activity. We aimed to develop immunotherapy strategies by vaccination with a mixture of HSP/
Ps (mHSP/Ps, HSP60, HSP70, Gp96 and HSP110) enhanced with cyclophosphamide (CY) and interleukin-12 (IL-12).
Methods: We extracted mHSP/Ps from the mouse sarcoma cell line S180 using chromatography. The identity of
proteins in this mHSP/Ps was assayed using SDS-PAGE and Western blot analysis with antibodies specific to various
HSPs. BALB/C mice bearing S180 cells were vaccinated with mHSP/Ps ×3, then were injected intraperitoneally with
low-dose CY and subcutaneously with IL-12, 100 μg/day, ×5. After vaccination, T lymphocytes in the peripheral
blood were analyzed using FACScan and Cytotoxicity (CTL) was analyzed using lactate dehydrogenase assay.
ELISPOT assay was used to evaluate interferon g (IFN-g), and immune cell infiltration in tumors was examined in
the sections of tumor specimen.
Results: In mice vaccinated with enhanced vaccine (mHSP/Ps and CY plus IL-12), 80% showed tumor regression
and long-term survival, and tumor growth inhibition rate was 82.3% (30 days), all controls died within 40 days.
After vaccination, lymphocytes and polymorphonuclear leukocytes infiltrated into the tumors of treated animals,
but no leukocytes infiltrated into the tumors of control mice. The proportions of natural killer cells, CD8+, and
interferon-g-secreting cells were all increased in the immune group, and tumor-specific cytotoxic T lymphocyte
activity was increased.
Conclusions: In this mice tumor model, vaccination with mHSP/Ps combined with low-dose CY plus IL-12 induced
an immunologic response and a marked antitumor response to autologous tumors. The regimen may be a
promising therapeutic agent against tumors.
Introduction
Some of the most abundant proteins in the cell belong
to the well-conserved family of proteins known as heat
shock proteins (HSPs), or glucose-regulated proteins
(GRPs). HSPs are present in all living cells; they can
exist in an unbound state or a state bound to specific
client proteins. HSPs function as molecular chaperones
in numerous processes, such as protein folding, assem-
bly and transport, peptide trafficking, and antigen pro-
cessing under physiologic and stress conditions [1,2].
Levels of HSPs are elevated in many cancers [3,4]. One
of the first identified HSP subtypes, Gp96, can reject
tumors [5]. HSP as a natural adjuvant can elicit in can-
cer patients a specific and active autoimmune response
to a tumor [6]. During tumor formation, HSPs increase
and bind to exposed hydrophobic tumor polypeptides.
HSP-chaperoned peptides enter antigen-presenting cells
through specific receptors and prime T cells by increas-
ing major histocompatibility complex (MHC) class I and
II-mediated antigen presentation [7-9]. The relevance of
the peptides associated with HSPs for inducing specific
immune responses is demonstrated by numerous stu-
dies, and GRP96, HSP70, HSP110 and GRP170 purified
from diverse tumors and functioning as tumor vaccines
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[10-13]. The factor is successful in CD8
+ Tc e l l -
dependent tumor clearance. The immune recognition
does not come from HSPs themselves but from binding
to peptides [14]. Some HSPs, such as HSP60 and
HSP70, augment natural killer (NK) cell activity, which
can also elicit innate immune responses [15,16].
As an alternative to selecting a single antigen for
tumor vaccine development, random mutations in can-
cer cells generate antigens unique to an individual. Puri-
fication of chaperone HSP from a cancer is believed to
co-purify an antigenic peptide “fingerprint” of the cell of
origin [17]. Thus, a vaccine comprising HSP/peptide
(HSP/P) complexes derived from a tumor, which would
include a full repertoire of patient-specific tumor
antigens, obviates the need to identify cytotoxic T-
lymphocyte (CTL) epitopes from individual cancers.
This advantage extends the use of chaperone-based
immunotherapy to cancers for which specific tumor
antigens have not yet been characterized [18].
After an extensive study, HSPs were found to augment
tumor antigen presentation and NK cell activity leading
to tumor lysis. Autologous patient-specific tumor vac-
cines have been generated by purifying HSP-antigen
complexes from tumor specimens and are currently
being evaluated in clinical trials. Preliminary clinical
trials with Gp96 used as a personalized vaccine for
immunotherapy in melanoma, renal, colon, ovarian can-
cer and non-Hodgkin lymphoma have reported results
[19-23]. HSP70 as a vaccine for leukemia was studied in
a clinical trial [24]. Although various immunotherapeu-
tic approaches have been examined for the treatment of
cancer, no such therapy has entered into the clinical
standard of care, and the therapeutic effects was not
satisfactory. Several challenges still need to be overcome.
Until now, all clinical trials have used the single sub-
type of HSPs, Gp96 or HSP70, whereas in a few animal
tumor models, the combination of Gp96 and HSP70 has
been shown to possess antitumor activity superior to
the that of each type alone [25]. These results suggest
that the mixture of several HSP subtypes may be more
effective in a broad range of tumor models. We used
the mixture of HSP/Ps (mHSP/Ps) that include HSP60,
HSP70, HSP110 and GRP96 as a vaccine and found an
effective prophylactic antitumor effect of the mHSP/Ps
in a mouse sarcoma model [26,27]. The effect protected
against tumor challenge in 50% of immunized mice, but
this strategy for the therapeutic treatment in already
established tumors were not satisfactory, so enhancing
the therapeutic immunity is needed.
Using cytokines to enhance immune reactivity has
been reported both in experimental and clinical trials
[28]. Interleukin 12 (IL-12) is still the most important
single cytokine in inducing antitumor immunity. In
experimental tumor models, recombinant IL-12 has
demonstrated marked antitumor effects through
mechanisms of both innate and adaptive immunity
[29,30]. The most unique antitumor activity of IL-12 is
its ability to eradicate established tumors [31,32]. How-
ever, the significant antitumor activity of IL-12 in these
models requires the presence of pre-existing immunity
in tumor-bearing hosts [33]. Thus, further improvement
of IL-12-based immunotherapy also depends on the
combination of vaccine-based modalities to establish
pre-existing immunity in tumor-bearing hosts.
When patients are diagnosed with cancer, by definition,
the tumor has “escaped” the immune system, having
passed the phases of “elimination” and “equilibrium.”
The generation of immune response against these anti-
gens is likely unproductive in the late stage because of
multiple immune tolerance mechanisms such as Treg
infiltration in the tumor bed, general immune suppres-
sion from immunosuppressive cytokines producing by
tumor cells, and downregulation of MHC class I mole-
cules on the tumor cells. Also, myeloid-derived suppres-
sor cells (MDSCs) and tumor-associated macrophages
(TAMs) create an immunosuppressive environment that
leads to suppression of T-cell responses [34,35]. Thus,
multiple immunological “brakes” need to be lifted to aug-
ment a productive immune response. Combined immu-
notherapeutic modalities need to be seriously considered.
The use of combination therapy with more than one
agent or modality is needed. To overcome the multiple
immune tolerance mechanisms, combinations of antican-
cer drugs and immunotherapy have been shown to
enhance tumor immunotherapy [36,37]. Treating mice
with low-dose cyclophosphamide (CY) decreased the
number of Tregs and enhanced the immunostimulatory
and antitumor effects [38-40].
To improve the efficacy of tumor immunotherapy, we
used the mHSP/P vaccine as an agent to induce pre-
existing immunity in a tumor-bearing mouse host, and
combined with CY plus IL-12 to eradicate established
large tumors in a therapeutic antitumor mouse model.
Methods
Animals and Cell Lines
6-8 weeks-old female BALB/C mice were obtained from
the Military Medical Academy of China (Beijing) and
bred in the General Hospital of the People’sL i b e r a t i o n
Army. The institutional animal care and use committee
approved the study protocols. The ascetic mouse S180
sarcoma cell line was obtained from the Military Medi-
cal Academy of China. The cell line was maintained by
serial passages in the BALB/C mouse peritoneal cavity.
Reagents
Anti-HSP60, anti-HSP70, anti-HSP110 and anti-Gp96/94
antibodies were obtained from Santa Cruz Biotechnology
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line A (ConA) and adenosine 5’-diphosphate (ADP) affi-
nity column were obtained from Pharmacia (US).
Recombinant murine IL-12 was provided by Dr. K.
Tsung at the Stanford School of Medicine. CY was
obtained from Heng Ray Pharmaceutical Co. (Jiangsu,
China).
HSP/P vaccine
mHSP/Ps were isolated from fresh, solid S180 subcuta-
neous tumors implanted in BALB/C mice. Tumor tissue
was homogenized by the use of a homogenizer at 4°C in
buffer (30 mM NaHCO3, pH 7.1) with freshly added
protease inhibitor phenyl-methylsulfonyl fluoride
(0.5 mM). The homogenate was centrifuged at 10,000 g
for 30 min at 4°C and the supernatant was then centri-
fuged at 100,000 g at 4°C for 2 h. The resulting superna-
tant was dialyzed against 20 mM Tris-HCl and 150 mM
NaCl, pH 7.2, and then was applied to Sephacryl
S-200HR. Bovine serum albumin was used as a molecu-
lar indicator in a pilot experiment to map the range of
eluted fractions. The tumor supernatant protein was
eluted with the same sample loading buffer. The col-
lected fractions of eluted protein underwent SDS-PAGE.
The fractions of #3 to #6 contained proteins of about
40-200 kDa. The combination of these 4 fractions was
used as the mHSP/Ps vaccine. The identity of proteins
in this combination was assayed using SDS-PAGE and
Western blot analysis with antibodies specific to various
HSPs.
In vivo antitumor experiments
To evaluate the antitumor activity of the mHSP/Ps pre-
paration, mice were divided into 6 groups for treatment
(n = 10 mice each): 1) normal saline control, 2) mHSP/
Ps, 3) CY plus IL-12, 4) mHSP/Ps plus IL-12, 5) mHSP/
Ps plus CY, 6) mHSP/Ps plus Cy plus IL-12.
All mice were subcutaneously injected in the back with
5×1 0
4 S 1 8 0c e l l s .O n ed a yl a t e r ,g r o u p sG r o u p s2 ,4 ,5 ,
and 6 mice were vaccinated 3 times at 7-day intervals
with 20 μg of mHSP/Ps. Groups 5 and 6 received 2 mg of
CY intraperitoneally 1 day after the last vaccination.
Groups 4 and 6 mice were subcutaneously injected with
IL-12, 100 ng/day, for 5 days, 3 days after a CY injection.
Group 3 mice received CY plus IL-12 at the same time as
Group 6, but the treatment started on day 16.
The antitumor effects were evaluated by tumor
volume, tumor growth inhibition rates, metastasis rate
and overall survival time. Tumor volume was deter-
mined by the measurement of the shortest (A) and long-
est diameter (B) using a caliper once every 3 days. The
volume (V) was calculated by the formula V = (A
2B/2).
Curative survival was considered to occur when the
tumor did not regrow or disappeared after more than
3 months. Lungs, liver and brains of dead mice were
removed and fixed in formalin, embedded in paraffin,
and sectioned at 5 μm. Hematoxylin & eosin (H&E)
stained samples were examined under a light micro-
scope (Olympus).
Analysis of immune response
Treatment of mice for analysis of immune responses
was the same as that for immunotherapy. Three days
after the combined therapy of mHSP/Ps and CY plus
IL-12, all mice were killed, and blood and spleen sam-
ples were collected. Mice from various control groups
were killed at the same time.
Assay for subgroup of T cells T lymphocytes in the
peripheral blood were analyzed using FACScan (Becton
Dickinson); cell staining involved a use of FITC- or phy-
coerythin-conjugated goat antibodies against mouse
CD4+, CD8+ and NK cells (Serotect, UK).
Cytotoxicity assays (CTL) Lactate dehydrogenase assay
was used to assess in vitro tumor-specific CTL response
to immunization with mHSP/Ps or mHSP/Ps and CY
plus IL-12. Three days after the final IL-12 administra-
tion, splenocytes were isolated by Ficoll-Paque density
centrifugation and were used as effector cells after resti-
mulation with ConA and mHSP/Ps in vitro for 4 days.
S180 as target cells were seeded in 96-well plates. The
lymphocytes were serially diluted and plated in 96-well
plates in triplicate with varying E:T ratios of 40:1, 20:1
and 5:1. Wells containing only target cells or only lym-
phocytes with culture medium or 0.5% Triton X-100
served as spontaneous or maximal release controls.
After 4-h incubation at 37°C and 5% CO2, 150-ul super-
natant was analyzed in a Well scan at OD 490 nm
(BioRad); the percentage of specific lysis was calculated
as follows:
% specific lysis = 100 × (experimental release -
spontaneous release)/(maximum release -
spontaneous release).
ELISPOT assay for evaluating interferon g (IFN-g)
Splenocytes were isolated by Ficoll-Paque density centri-
fugation. 2 × 10
5 cells were incubated with ConA (8 μg/
ml) or additionally restimulated with mHSP/Ps (10 μg/
ml) for 5 days in 96-well ELISPOT plates coated with
antibody to bind murine IFN-g. The assays followed the
kit manufacturer’s instructions (U-CyTech B.V.
Holland).
Immune cell infiltration in tumors Tumor tissue was
removed after mice were killed, fixed in formalin,
embedded in paraffin, and sectioned at 5 μm. H&E-
stained tissues were examined under a light microscope.
Statistical analysis
All experiments were performed in triplicate, and the
data were presented as mean± SD. Statistical analysis
involved a use of SPSS 13.0 (SPSS Inst., Chicago, IL).
Data were shown as means ± SD. A two-tailed paired
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IFN-g levels of the experimental and control groups. A
P < 0.05 was considered statistically significant.
Results
Preparation of mHSP/Ps
The combination of 4 protein fractions was eluted from
S180 tumor cells. The presence of the various HSPs –
HSP60, HSP70, Gp96 and HSP110 – in the crude pre-
paration was identified by SDS-PAGE and Western blot
analysis (Figure 1). As indicated in SDS-PAGE, there
were many bands for proteins other than HSPs in the
sample, and components of HSP60, HSP70, Gp96 and
HSP110 were identified by Western blot, with their pur-
ity of 90% in total proteins.
Therapeutic antitumor effects of mHSP/Ps and CY plus
IL-12 treatment in mouse sarcoma tumor model
All 10 mice treated with saline alone died within 40
days because of tumor burden. Some of these mice had
tumor metastases in the lung before death. Vaccination
with mHSP/Ps alone and mHSP/Ps plus IL-12 (starting
on day 19) also had no antitumor effects. In mice vacci-
nated with mHSP/Ps plus CY (day 16), 10% showed era-
dicated tumors. In mice vaccinated with CY plus IL-12
(starting on day 16), 30% showed eradicated tumors. In
comparison, in mice vaccinated with mHSP/Ps followed
by Cy plus IL-12 (starting on day 16), 80% showed era-
dicated tumors (Figure 2). The mean survival time,
except long-term survival, for groups was as follows: sal-
ine control, 35.5 days; mHSP/Ps, 32.4 days; mHSP/Ps
plus IL-12, 40.1 days; mHSP/Ps plus CY, 37.3 days; CY
plus IL-1, 37.4 days; and mHSP/Ps plus CY plus
IL-12:,48 days.
The tumor growth curve of S180 tumors in BALB/C
mice after vaccination with mHSP/Ps plus CY plus IL-12
was less steep than that for all control groups (Figure 3),
so tumor progression was inhibited substantially.
To determine whether this antitumor activity induced
long-term immunity against tumors, we challenged mice
that survived with 5 × 10
4 S180 cells 15 months after the
first challenge with the same cell line. No tumors devel-
oped in any mice, which indicated that long-term immu-
nological memory against the S180 tumor was associated
with tumor eradication by our immunotherapy.
mHSP/Ps and mHSP/Ps plus CY plus IL-12 induce immune
reaction
Change of immune cell population with various vac-
cinations In naïve mice, the mean proportion of CD8+
cells in total mononuclear cells was 5.89 ± 0.36%. At the
late stage of tumor-bearing (day 26), the proportion of
CD8+ T cells was suppressed to 1.26%. Treatment with
mHSP/Ps increased the proportion of CD8+ T cells to
9.1 5% at about the same time of tumor establishment
        
1      2     3     4     5    6  
A      1      2      3  
B 
Figure 1 SDS-PAGE and western blot analysis of mixed HSP/Ps from S180 sarcoma. A. SDS-PAGE of mHSP/P from S180; Lane1, molecular
standard, Line2,3 collection of F3-F6 from Sephacryl S-200HR. There were many protein bands other than MW60, 70, 96 and110. B. Western blot:
Lane 1, SDS-PAGE, molecular standard. 2, SDS-PAGE, collection of F3-F6, Line3 analysis with antibodies against HSP60, Line4 analysis with
antibodies against HSP70, Line5 analysis with antibodies against Gp96, and Line6 analysis with antibodies against HSP110. Identified The mixture
included HSP60, HSP70, Gp96 and HSP110.
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the CD8+ population was higher (9.21 ± 1.45%) than
that in mHSP/P-treated mice and untreated tumor-bear-
ing mice. Similar to the proportion of CD8+ T cells,
that of CD4+ T cells was suppressed in late-stage
tumor-bearing mice. Treatment with mHSP/Ps plus CY
plus IL-12 increased the ratio of CD4+ T cells. In mice
treated with normal saline, the mean NK cell in total
mononuclear cells was 1.70% ± 0.32%. Again, in tumor-
bearing mice, the ratio of NK cells was suppressed to
0.19%. This ratio was increased to 4.98% with mHSP/Ps
alone and was even greater with mHSP/Ps plus CY plus
IL-12 (5.72%).
Number of INF-g-secreting cells was elevated with
mHSP/Ps and CY plus IL-12 vaccination To deter-
mine whether vaccination with mHSP/Ps results in
increased number of antigen-specific Th1 cells and IFN-
g-producing NK cells, the number of IFN-g-secreting
splenocytes was determined by an in vitro assay of IFN-
gamma ELISPOT. The frequency of IFN-g-producing
splenocytes increased with ConA alone or ConA plus
mHSP/Ps in vitro (Figure 4). Under both stimulation
conditions, splenocytes from mice treated with both
mHSP/Ps alone and mHSP/Ps plus CY plus IL-12
showed an increased number of IFN-gamma-producing
cells, with the later treatment giving the higher number.
The number of IFN-g elicited by mHSP/P+Cy+IL12 vac-
cination was significantly higher than that of tumor
bearing mice and naïve mice, P < 0.05.
CTLs generated by mHSP/Ps plus CY plus IL12 are
capable of killing target cells To assess the functional
effector properties of CTLs generated by mHSP/Ps plus
CY plus IL-12, we performed in vitro cytotoxicity assays of
lymphocytes isolated from mice treated with mHSP/Ps
plus CY plus IL-12. The cytolytic activity of effector cells
was measured by lactate dehydrogenase assay. Target cells
(S180) pulsed with effector splenocyte cells from mice trea-
ted with mHSP/Ps were killed to some extent by CTLs, an
amount higher than in those pulsed with splenocytes from
naïve mice or tumor-bearing mice not treated with mHSP/
Ps (Figure 5). The cytolysis percentage of mHSP/P+Cy
+IL12 vaccine was significantly higher than that of mHSP/
Ps vaccine and naïve mice, P < 0.05, and that of tumor
bearing mice, P < 0.01. In addition, the proportion of lysis
of lymphocytes to rabbit liver cancer cells vx2 was very
low, 4% in E/T = 5 and 10% in E/T = 20.
Lymphocytes and leukocytes were recruited to tumor
lesions In histological examination of tumor lesions of
immunized mice, leukocytes were found to have infil-
trated tumor lesions since numerous lymphocytes were
collected in blood vessels and near blood vessel walls,
whereas no leukocytes were found to have infiltrated
tumors of mice without vaccine (Figure 6). This result
showed that pre-immunization was induced after
mHSP/Ps immunization.
Discussion
Vaccination with HSP/Ps is personalized, delivering tumor
antigen as a fingerprint genome. The vaccine is polyva-
lence. Here we developed a vaccine with a mixture of
HSP/Ps which, in addition to HSP70 or Gp96, also
included HSp60 and HSP110. The antitumor effects of
this mHSP/Ps vaccine were more potent than those of
HSP70 or HSP60 alone and of tumor lysates used as vac-
cine in prophylactic immunization, Table 1. [25]. When
using this mHSP/P vaccine in mice after tumor transplan-
tation (therapeutic immunization), the antitumor action
was not effective, as we showed in this study. The efficacy
of therapeutic immunization was effective only in the
combination therapy that used immunotherapeutic
mHSP/Ps combined with CY and IL-12.
For specific immunotherapy, the identical MHC
genetic molecules are important, We had no informa-
tion about the MHC genetic molecules of S180 or
MCA-207 when we selected the mouse sarcoma cell
lines S180 and MCA-207 as models. However, from
reported experimental information and our experiments,
we knew that the S180 sarcoma cell lines can grow both
in BALB/C and C57 mice, as in our control group, in
which all the S180 tumors grew and were not rejected.
This finding suggests S180 and BALB/C mice have the
matched MHC locus even in allogenic transplantation.
The MCA-207 only grew in C57 mice but was rejected
in BALB/C mice, and this result suggests that the MHC
of MCA-207 matched only with the MHC of C57 mice;
therefore, in our animal models, the allogenic immune
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Figure 2 Effect of various mHSP/P vaccinations on the survival
of S180 tumor-bearing mice. * The number of mouse in each
group is 10.
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tumor effects were not related to unmatched MHC.
To identify the specificity of mHSP/P vaccine, we
compared the cytolysis ratio of mHSP/Ps isolated from
liver and muscle of naïve mice in vitro and saw no cyto-
lytic effect against S180 sarcoma. The cytolysis ratio was
lower than 1%. Also, we compared the mHSP/p of S180
against rabbit liver cancer cell line vx2, and the cytolysis
effect was lower than 10%, [data not shown]. In addi-
tion, we found that the mice vaccinated with mHSP/P
of MCA207 were protected only against MCA207 but
not S180 in vivo. Thus, the mHSP/P-induced immune
reaction may be autologous tumor-specific, like indivi-
dual vaccines.
Figure 3 Tumor growth curve of S180 tumor in BALB/C mice after various treatments.
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genic tumors. In our study, the combination of IL-12 and
Cy eradicated tumors in 30% of mice, and in IL-12-trea-
ted mice, all tumor mass necrosis and an ulcer formed
before tumor eradication, suggesting the anti-angiogen-
esis activity of IL-12 was involved [41], When we com-
b i n e dm H S P / P sw i t hC Ya n dI L - 1 2t oe n h a n c et h e
immunization efficacy, the antitumor efficacy enhanced.
However, with mHSP/Ps and CY alone or with mHSP/Ps
and IL-12 alone, the antitumor efficacy was not
improved. Our results suggested that one potential
mechanism of mHSP/Ps and CY plus IL-12 in augment-
ing therapeutic immunotherapy strategies was that
mHSP/P immunization activated the antitumor immuni-
zation, and at the same time, also induced the T-cell tol-
erance directed toward tumor-associated antigens and
limited the repertoire of functional tumor-reactive T
cells. Therefore, the ability of vaccines to elicit effective
antitumor immunity was impaired. CY has immunomo-
dulatory effects, and low-dose CY (20 mg/kg) was found
to selectively deplete CD4+CD25+ T cells (Treg) and
impede the tolerance [42]. CY can preconditioning
enhance the CD8+ T-cell response to peptide vaccina-
tion, thus leading to enhanced antitumor effects against
pre-existing tumors [43]. Cy markedly enhanced the
magnitude of secondary but not primary CTL response
induced by vaccines and synergized with vaccine in ther-
apy but not in prophylaxis tumor models [44].
With our enhanced vaccine, IFN-g secretion was sig-
nificantly increased. In addition, CD8+ and NK cells
were triggered to release IFN-g and mediate cytotoxic
activity. The increased IFN-g secretion may also be due
to the combined effects of HSP60 in mHSP/P and IL-
12. Hsp60-inducing IFN-g depends strictly on the ability
of the macrophages to produce IL-12 [45].
Activation and expansion of tumor-specific T cells by
HSP/Ps were identified [46]. Our study showed that
mHSP/Ps purified from S180 sarcoma cells activated
tumor antigen-specific T cells in vitro, and the induction
of tumor-specific CTLs with enhanced vaccine was
stronger than that with mHSP/Ps alone, possibly
because of the combined effect of HSP60 and IL-12.
HSP60 induces a strong non-specific immune reaction,
but when it meets IL-12, it can activate cytotoxic T
cells. HSP60 can mediate the activation of cytotoxic T
cells, which depends on production of IL-12 [47].
Our data showed that inflammatory cells infiltrated
tumors with mHSP/P vaccination and that a preexisting
antitumor immune response was elicited, which was
required for an effective IL-12 response for tumor
rejection.
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Figure 6 Lymphocytes infiltration in tumor of mHSP/P
immunized mice. A leukocytes infiltration into tumor lesion after
mHSP/P immunization, X40. B lymphocytes in blood vessels after
mHSP/P immunization, X40. C No lymphocytes infiltration in tumor
lesion after NS treatment, X40. Which revolved preimmunization
after mHSP/P immunization.
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To enhance the current immunotherapeutic efficacy,
novel strategies designed in the laboratory and proven
in preclinical animal tumor models are now entering the
clinic trials [48,49]. These novel strategies involved
breaking tolerance to tumor self-antigens by inhibiting
regulatory T cells, boosting T-cell co-stimulation and
using combinations of recombinant cytokines and other
defined molecules with “immuno-enhancing” activities.
Our immunization protocol of a combination immu-
notherapeutic regimen of vaccination with mHSP/Ps fol-
lowed by low-dose CY plus IL-12 resulted in enhanced
immunologic antitumor activity that was better than
that of either treatment alone.
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